fasudil
Sign in to saveAlso known as HA 1077, HA1077
Fasudil (INN) is a potent Rho-kinase inhibitor and vasodilator. Since it was discovered, it has been used for the treatment of cerebral vasospasm, which is often due to subarachnoid hemorrhage, as well as to improve the cognitive decline seen in stroke patients. It has been found to be effective for the treatment of pulmonary hypertension. It has been demonstrated that fasudil could improve memory in normal mice, identifying the drug as a possible treatment for age-related or neurodegenerative memory loss.
Research
1,678 papers- Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
- Multicenter SPAN Trial of Fasudil in Ischemic Stroke.Stroke · 2025
- Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.The Lancet. Neurology · 2024
- RECOVER study: a multicenter retrospective cohort study and comparison of the efficacy and safety of clazosentan and fasudil in patients with aneurysmal subarachnoid hemorrhage.Journal of neurosurgery · 2025
- Fasudil inhibits α-synuclein aggregation through ROCK-inhibition-mediated mechanisms.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
via PubMed
Wikidata facts
- Mass
- 291.104
Show 3 more facts
- chemical formula
- C₁₄H₁₇N₃O₂S
- canonical SMILES
- C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3
- Commons category
- Fasudil
via Wikidata · CC0
~4 min read
Article
7 sectionsContents
- Molecular mechanism
- ACE expression
- eNOS expression
- ERK activation
- Direct inhibition of α-synuclein aggregation
- See also
- References
Fasudil (INN) is a potent Rho-kinase inhibitor and vasodilator. Since it was discovered, it has been used for the treatment of cerebral vasospasm, which is often due to subarachnoid hemorrhage, as well as to improve the cognitive decline seen in stroke patients. It has been found to be effective for the treatment of pulmonary hypertension. It has been demonstrated that fasudil could improve memory in normal mice, identifying the drug as a possible treatment for age-related or neurodegenerative memory loss.
It has been approved for use in Japan and China since 1995, but has not been approved by the United States Food and Drug Administration or by the European Medicines Agency. Woolsey Pharmaceuticals is developing BRAVYL (oral fasudil) for various neurodegenerative diseases.